Cargando…

A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study

BACKGROUND: Remote monitoring of Huntington disease (HD) signs and symptoms using digital technologies may enhance early clinical diagnosis and tracking of disease progression, guide treatment decisions, and monitor response to disease-modifying agents. Several recent studies in neurodegenerative di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipsmeier, Florian, Simillion, Cedric, Bamdadian, Atieh, Tortelli, Rosanna, Byrne, Lauren M, Zhang, Yan-Ping, Wolf, Detlef, Smith, Anne V, Czech, Christian, Gossens, Christian, Weydt, Patrick, Schobel, Scott A, Rodrigues, Filipe B, Wild, Edward J, Lindemann, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277525/ https://www.ncbi.nlm.nih.gov/pubmed/35763342 http://dx.doi.org/10.2196/32997

Ejemplares similares

Deep Learning-Based Human Activity Recognition for Continuous Activity and Gesture Monitoring for Schizophrenia Patients With Negative Symptoms
por: Umbricht, Daniel, et al.
Publicado: (2020)

The use of wearable/portable digital sensors in Huntington's disease: A systematic review
por: Tortelli, Rosanna, et al.
Publicado: (2021)

Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson’s disease
por: Lipsmeier, Florian, et al.
Publicado: (2022)

Gait Characteristics Harvested during a Smartphone-Based Self-Administered 2-Minute Walk Test in People with Multiple Sclerosis: Test-Retest Reliability and Minimum Detectable Change
por: Bourke, Alan K., et al.
Publicado: (2020)

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease
por: Lowe, Alexander J., et al.
Publicado: (2020)

Look me in the eye: evaluating the accuracy of smartphone-based eye tracking for potential application in autism spectrum disorder research
por: Strobl, Maximilian A. R., et al.
Publicado: (2019)

Lumbar puncture safety and tolerability in premanifest and manifest Huntington’s disease: a multi-analysis cross-sectional study
por: Hassan, Yara Refaat, et al.
Publicado: (2022)

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease
por: Rodrigues, Filipe B., et al.
Publicado: (2021)

Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease
por: Lowe, Alexander J, et al.
Publicado: (2022)

Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease
por: Ou, Zhen-Yi Andy, et al.
Publicado: (2021)

Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study
por: Midaglia, Luciana, et al.
Publicado: (2019)

Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study
por: Midaglia, Luciana, et al.
Publicado: (2019)

Interpretable deep learning for the remote characterisation of ambulation in multiple sclerosis using smartphones
por: Creagh, Andrew P., et al.
Publicado: (2021)

Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis
por: Graves, Jennifer S., et al.
Publicado: (2022)

Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial
por: Lipsmeier, Florian, et al.
Publicado: (2018)

Beacon-Based Remote Measurement of Social Behavior in ASD Clinical Trials: A Technical Feasibility Assessment
por: Kriara, Lito, et al.
Publicado: (2021)

Psychogenic non-epileptic seizures in early Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Huntington’s Disease Clinical Trials Corner: February 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Huntington’s Disease Clinical Trials Corner: August 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Huntington’s Disease Clinical Trials Corner: June 2019
por: Rodrigues, Filipe B., et al.
Publicado: (2019)

Prodromal Huntington Disease as a Model for Functional Compensation of Early Neurodegeneration
por: Malejko, Kathrin, et al.
Publicado: (2014)

Characterizing White Matter in Huntington's Disease
por: Gregory, Sarah, et al.
Publicado: (2019)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children
por: Byrne, Lauren M., et al.
Publicado: (2022)

Effect of Body Weight on Age at Onset in Huntington Disease: A Mendelian Randomization Study
por: van der Burg, Jorien M.M., et al.
Publicado: (2021)

Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI
por: Rodrigues, Filipe B., et al.
Publicado: (2019)

A smartphone sensor-based digital outcome assessment of multiple sclerosis
por: Montalban, Xavier, et al.
Publicado: (2021)

Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?
por: Rodrigues, Filipe B., et al.
Publicado: (2017)

The gene coding for PGC-1α modifies age at onset in Huntington's Disease
por: Weydt, Patrick, et al.
Publicado: (2009)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort
por: Weydt, Patrick, et al.
Publicado: (2014)

Patient Recruitment 2.0: Become a Partner in the Patient Journey Using Digital Media
por: Lindemann, Michael, et al.
Publicado: (2016)

Changes in brain activity with tominersen in early-manifest Huntington’s disease
por: Hawellek, D J, et al.
Publicado: (2022)

Nucleolar stress controls mutant Huntington toxicity and monitors Huntington’s disease progression
por: Sönmez, Aynur, et al.
Publicado: (2021)

Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY
por: Orth, Michael, et al.
Publicado: (2011)

Natural history and burden of Huntington's disease in the UK: A population‐based cohort study
por: Furby, Hannah, et al.
Publicado: (2022)

Neural Compensation in Huntington's Disease: Teaching Mental Disorders New Tricks?
por: Wolf, Robert Christian, et al.
Publicado: (2015)

Cortical neurodevelopment in pre-manifest Huntington's disease
por: Kubera, Katharina M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oqobfchpt506b04bfrtisup4mf